

Global Neurodegenerative Drugs Market Growth 2025-2031

<https://marketpublishers.com/r/G9ED8B4E7A9DEN.html>

Date: October 2025

Pages: 132

Price: US\$ 3,660.00 (Single User License)

ID: G9ED8B4E7A9DEN

Abstracts

The global Neurodegenerative Drugs market size is predicted to grow from US\$ 132880 million in 2025 to US\$ 190180 million in 2031; it is expected to grow at a CAGR of 6.2% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Neurodegenerative drugs are medications used to manage and alleviate symptoms associated with neurodegenerative diseases. They may target various aspects of disease progression, such as cognitive function, motor symptoms, and inflammation.

The market for neurodegenerative drugs is driven by the growing burden of neurodegenerative diseases and the need for effective and disease-modifying treatments. The market's growth is also influenced by ongoing research in neuroscience and the development of novel drug candidates targeting specific neurodegenerative pathways.

LP Information, Inc. (LPI) ' newest research report, the "Neurodegenerative Drugs Industry Forecast" looks at past sales and reviews total world Neurodegenerative Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Neurodegenerative Drugs sales for 2025 through 2031. With Neurodegenerative Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Neurodegenerative Drugs industry.

This Insight Report provides a comprehensive analysis of the global Neurodegenerative Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neurodegenerative Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Neurodegenerative Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurodegenerative Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurodegenerative Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Neurodegenerative Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

NMDA

SSRIs

Dopamine Inhibitors

Segmentation by Application:

Parkinson's Disease

Huntington Disease

Amyotrophic Lateral Sclerosis

Alzheimer's Disease

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Novartis

Pfizer

Merck Serono

Biogen Idec

TEVA

UCB

Boehringer Ingelheim

Sanofi

GlaxoSmithKline

Livzon Pharmaceutical

Haisco Pharmaceutical

Jingxin Pharmaceutical

Dongcheng Biochemicals

Hisun Pharmaceutical

Luye Pharma

Ark Pharmaceutical

Kanghong Pharmaceutical

Huahai Pharmaceutical

BORA PHARMACEUTICALS

Key Questions Addressed in this Report

What is the 10-year outlook for the global Neurodegenerative Drugs market?

What factors are driving Neurodegenerative Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Neurodegenerative Drugs market opportunities vary by end market size?

How does Neurodegenerative Drugs break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Neurodegenerative Drugs Annual Sales 2020-2031
 - 2.1.2 World Current & Future Analysis for Neurodegenerative Drugs by Geographic Region, 2020, 2024 & 2031
 - 2.1.3 World Current & Future Analysis for Neurodegenerative Drugs by Country/Region, 2020, 2024 & 2031
- 2.2 Neurodegenerative Drugs Segment by Type
 - 2.2.1 NMDA
 - 2.2.2 SSRIs
 - 2.2.3 Dopamine Inhibitors
- 2.3 Neurodegenerative Drugs Sales by Type
 - 2.3.1 Global Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
 - 2.3.2 Global Neurodegenerative Drugs Revenue and Market Share by Type (2020-2025)
 - 2.3.3 Global Neurodegenerative Drugs Sale Price by Type (2020-2025)
- 2.4 Neurodegenerative Drugs Segment by Application
 - 2.4.1 Parkinson's Disease
 - 2.4.2 Huntington Disease
 - 2.4.3 Amyotrophic Lateral Sclerosis
 - 2.4.4 Alzheimer's Disease
- 2.5 Neurodegenerative Drugs Sales by Application
 - 2.5.1 Global Neurodegenerative Drugs Sale Market Share by Application (2020-2025)
 - 2.5.2 Global Neurodegenerative Drugs Revenue and Market Share by Application (2020-2025)

2.5.3 Global Neurodegenerative Drugs Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Neurodegenerative Drugs Breakdown Data by Company

3.1.1 Global Neurodegenerative Drugs Annual Sales by Company (2020-2025)

3.1.2 Global Neurodegenerative Drugs Sales Market Share by Company (2020-2025)

3.2 Global Neurodegenerative Drugs Annual Revenue by Company (2020-2025)

3.2.1 Global Neurodegenerative Drugs Revenue by Company (2020-2025)

3.2.2 Global Neurodegenerative Drugs Revenue Market Share by Company (2020-2025)

3.3 Global Neurodegenerative Drugs Sale Price by Company

3.4 Key Manufacturers Neurodegenerative Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Neurodegenerative Drugs Product Location Distribution

3.4.2 Players Neurodegenerative Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR NEURODEGENERATIVE DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Neurodegenerative Drugs Market Size by Geographic Region (2020-2025)

4.1.1 Global Neurodegenerative Drugs Annual Sales by Geographic Region (2020-2025)

4.1.2 Global Neurodegenerative Drugs Annual Revenue by Geographic Region (2020-2025)

4.2 World Historic Neurodegenerative Drugs Market Size by Country/Region (2020-2025)

4.2.1 Global Neurodegenerative Drugs Annual Sales by Country/Region (2020-2025)

4.2.2 Global Neurodegenerative Drugs Annual Revenue by Country/Region (2020-2025)

4.3 Americas Neurodegenerative Drugs Sales Growth

4.4 APAC Neurodegenerative Drugs Sales Growth

4.5 Europe Neurodegenerative Drugs Sales Growth

4.6 Middle East & Africa Neurodegenerative Drugs Sales Growth

5 AMERICAS

5.1 Americas Neurodegenerative Drugs Sales by Country

5.1.1 Americas Neurodegenerative Drugs Sales by Country (2020-2025)

5.1.2 Americas Neurodegenerative Drugs Revenue by Country (2020-2025)

5.2 Americas Neurodegenerative Drugs Sales by Type (2020-2025)

5.3 Americas Neurodegenerative Drugs Sales by Application (2020-2025)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Neurodegenerative Drugs Sales by Region

6.1.1 APAC Neurodegenerative Drugs Sales by Region (2020-2025)

6.1.2 APAC Neurodegenerative Drugs Revenue by Region (2020-2025)

6.2 APAC Neurodegenerative Drugs Sales by Type (2020-2025)

6.3 APAC Neurodegenerative Drugs Sales by Application (2020-2025)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Neurodegenerative Drugs by Country

7.1.1 Europe Neurodegenerative Drugs Sales by Country (2020-2025)

7.1.2 Europe Neurodegenerative Drugs Revenue by Country (2020-2025)

7.2 Europe Neurodegenerative Drugs Sales by Type (2020-2025)

7.3 Europe Neurodegenerative Drugs Sales by Application (2020-2025)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Neurodegenerative Drugs by Country

8.1.1 Middle East & Africa Neurodegenerative Drugs Sales by Country (2020-2025)

8.1.2 Middle East & Africa Neurodegenerative Drugs Revenue by Country (2020-2025)

8.2 Middle East & Africa Neurodegenerative Drugs Sales by Type (2020-2025)

8.3 Middle East & Africa Neurodegenerative Drugs Sales by Application (2020-2025)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Neurodegenerative Drugs

10.3 Manufacturing Process Analysis of Neurodegenerative Drugs

10.4 Industry Chain Structure of Neurodegenerative Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Neurodegenerative Drugs Distributors

11.3 Neurodegenerative Drugs Customer

12 WORLD FORECAST REVIEW FOR NEURODEGENERATIVE DRUGS BY GEOGRAPHIC REGION

- 12.1 Global Neurodegenerative Drugs Market Size Forecast by Region
 - 12.1.1 Global Neurodegenerative Drugs Forecast by Region (2026-2031)
 - 12.1.2 Global Neurodegenerative Drugs Annual Revenue Forecast by Region (2026-2031)
- 12.2 Americas Forecast by Country (2026-2031)
- 12.3 APAC Forecast by Region (2026-2031)
- 12.4 Europe Forecast by Country (2026-2031)
- 12.5 Middle East & Africa Forecast by Country (2026-2031)
- 12.6 Global Neurodegenerative Drugs Forecast by Type (2026-2031)
- 12.7 Global Neurodegenerative Drugs Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

- 13.1 Novartis
 - 13.1.1 Novartis Company Information
 - 13.1.2 Novartis Neurodegenerative Drugs Product Portfolios and Specifications
 - 13.1.3 Novartis Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.1.4 Novartis Main Business Overview
 - 13.1.5 Novartis Latest Developments
- 13.2 Pfizer
 - 13.2.1 Pfizer Company Information
 - 13.2.2 Pfizer Neurodegenerative Drugs Product Portfolios and Specifications
 - 13.2.3 Pfizer Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.2.4 Pfizer Main Business Overview
 - 13.2.5 Pfizer Latest Developments
- 13.3 Merck Serono
 - 13.3.1 Merck Serono Company Information
 - 13.3.2 Merck Serono Neurodegenerative Drugs Product Portfolios and Specifications
 - 13.3.3 Merck Serono Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.3.4 Merck Serono Main Business Overview
 - 13.3.5 Merck Serono Latest Developments
- 13.4 Biogen Idec
 - 13.4.1 Biogen Idec Company Information
 - 13.4.2 Biogen Idec Neurodegenerative Drugs Product Portfolios and Specifications
 - 13.4.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue, Price and Gross

Margin (2020-2025)

13.4.4 Biogen Idec Main Business Overview

13.4.5 Biogen Idec Latest Developments

13.5 TEVA

13.5.1 TEVA Company Information

13.5.2 TEVA Neurodegenerative Drugs Product Portfolios and Specifications

13.5.3 TEVA Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin

(2020-2025)

13.5.4 TEVA Main Business Overview

13.5.5 TEVA Latest Developments

13.6 UCB

13.6.1 UCB Company Information

13.6.2 UCB Neurodegenerative Drugs Product Portfolios and Specifications

13.6.3 UCB Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin

(2020-2025)

13.6.4 UCB Main Business Overview

13.6.5 UCB Latest Developments

13.7 Boehringer Ingelheim

13.7.1 Boehringer Ingelheim Company Information

13.7.2 Boehringer Ingelheim Neurodegenerative Drugs Product Portfolios and Specifications

13.7.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)

13.7.4 Boehringer Ingelheim Main Business Overview

13.7.5 Boehringer Ingelheim Latest Developments

13.8 Sanofi

13.8.1 Sanofi Company Information

13.8.2 Sanofi Neurodegenerative Drugs Product Portfolios and Specifications

13.8.3 Sanofi Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin

(2020-2025)

13.8.4 Sanofi Main Business Overview

13.8.5 Sanofi Latest Developments

13.9 GlaxoSmithKline

13.9.1 GlaxoSmithKline Company Information

13.9.2 GlaxoSmithKline Neurodegenerative Drugs Product Portfolios and Specifications

13.9.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)

13.9.4 GlaxoSmithKline Main Business Overview

- 13.9.5 GlaxoSmithKline Latest Developments
- 13.10 Livzon Pharmaceutical
 - 13.10.1 Livzon Pharmaceutical Company Information
 - 13.10.2 Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
 - 13.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.10.4 Livzon Pharmaceutical Main Business Overview
 - 13.10.5 Livzon Pharmaceutical Latest Developments
- 13.11 Haisco Pharmaceutical
 - 13.11.1 Haisco Pharmaceutical Company Information
 - 13.11.2 Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
 - 13.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.11.4 Haisco Pharmaceutical Main Business Overview
 - 13.11.5 Haisco Pharmaceutical Latest Developments
- 13.12 Jingxin Pharmaceutical
 - 13.12.1 Jingxin Pharmaceutical Company Information
 - 13.12.2 Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
 - 13.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.12.4 Jingxin Pharmaceutical Main Business Overview
 - 13.12.5 Jingxin Pharmaceutical Latest Developments
- 13.13 Dongcheng Biochemicals
 - 13.13.1 Dongcheng Biochemicals Company Information
 - 13.13.2 Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolios and Specifications
 - 13.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.13.4 Dongcheng Biochemicals Main Business Overview
 - 13.13.5 Dongcheng Biochemicals Latest Developments
- 13.14 Hisun Pharmaceutical
 - 13.14.1 Hisun Pharmaceutical Company Information
 - 13.14.2 Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
 - 13.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)

- 13.14.4 Hisun Pharmaceutical Main Business Overview
- 13.14.5 Hisun Pharmaceutical Latest Developments
- 13.15 Luye Pharma
 - 13.15.1 Luye Pharma Company Information
 - 13.15.2 Luye Pharma Neurodegenerative Drugs Product Portfolios and Specifications
 - 13.15.3 Luye Pharma Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.15.4 Luye Pharma Main Business Overview
 - 13.15.5 Luye Pharma Latest Developments
- 13.16 Ark Pharmaceutical
 - 13.16.1 Ark Pharmaceutical Company Information
 - 13.16.2 Ark Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
 - 13.16.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.16.4 Ark Pharmaceutical Main Business Overview
 - 13.16.5 Ark Pharmaceutical Latest Developments
- 13.17 Kanghong Pharmaceutical
 - 13.17.1 Kanghong Pharmaceutical Company Information
 - 13.17.2 Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
 - 13.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.17.4 Kanghong Pharmaceutical Main Business Overview
 - 13.17.5 Kanghong Pharmaceutical Latest Developments
- 13.18 Huahai Pharmaceutical
 - 13.18.1 Huahai Pharmaceutical Company Information
 - 13.18.2 Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
 - 13.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.18.4 Huahai Pharmaceutical Main Business Overview
 - 13.18.5 Huahai Pharmaceutical Latest Developments
- 13.19 BORA PHARMACEUTICALS
 - 13.19.1 BORA PHARMACEUTICALS Company Information
 - 13.19.2 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolios and Specifications
 - 13.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)

13.19.4 BORA PHARMACEUTICALS Main Business Overview

13.19.5 BORA PHARMACEUTICALS Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Neurodegenerative Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Table 2. Neurodegenerative Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)

Table 3. Major Players of NMDA

Table 4. Major Players of SSRIs

Table 5. Major Players of Dopamine Inhibitors

Table 6. Global Neurodegenerative Drugs Sales by Type (2020-2025) & (MT)

Table 7. Global Neurodegenerative Drugs Sales Market Share by Type (2020-2025)

Table 8. Global Neurodegenerative Drugs Revenue by Type (2020-2025) & (\$ million)

Table 9. Global Neurodegenerative Drugs Revenue Market Share by Type (2020-2025)

Table 10. Global Neurodegenerative Drugs Sale Price by Type (2020-2025) & (US\$/MT)

Table 11. Global Neurodegenerative Drugs Sale by Application (2020-2025) & (MT)

Table 12. Global Neurodegenerative Drugs Sale Market Share by Application (2020-2025)

Table 13. Global Neurodegenerative Drugs Revenue by Application (2020-2025) & (\$ million)

Table 14. Global Neurodegenerative Drugs Revenue Market Share by Application (2020-2025)

Table 15. Global Neurodegenerative Drugs Sale Price by Application (2020-2025) & (US\$/MT)

Table 16. Global Neurodegenerative Drugs Sales by Company (2020-2025) & (MT)

Table 17. Global Neurodegenerative Drugs Sales Market Share by Company (2020-2025)

Table 18. Global Neurodegenerative Drugs Revenue by Company (2020-2025) & (\$ millions)

Table 19. Global Neurodegenerative Drugs Revenue Market Share by Company (2020-2025)

Table 20. Global Neurodegenerative Drugs Sale Price by Company (2020-2025) & (US\$/MT)

Table 21. Key Manufacturers Neurodegenerative Drugs Producing Area Distribution and Sales Area

Table 22. Players Neurodegenerative Drugs Products Offered

Table 23. Neurodegenerative Drugs Concentration Ratio (CR3, CR5 and CR10) &

(2023-2025)

Table 24. New Products and Potential Entrants

Table 25. Market M&A Activity & Strategy

Table 26. Global Neurodegenerative Drugs Sales by Geographic Region (2020-2025) & (MT)

Table 27. Global Neurodegenerative Drugs Sales Market Share Geographic Region (2020-2025)

Table 28. Global Neurodegenerative Drugs Revenue by Geographic Region (2020-2025) & (\$ millions)

Table 29. Global Neurodegenerative Drugs Revenue Market Share by Geographic Region (2020-2025)

Table 30. Global Neurodegenerative Drugs Sales by Country/Region (2020-2025) & (MT)

Table 31. Global Neurodegenerative Drugs Sales Market Share by Country/Region (2020-2025)

Table 32. Global Neurodegenerative Drugs Revenue by Country/Region (2020-2025) & (\$ millions)

Table 33. Global Neurodegenerative Drugs Revenue Market Share by Country/Region (2020-2025)

Table 34. Americas Neurodegenerative Drugs Sales by Country (2020-2025) & (MT)

Table 35. Americas Neurodegenerative Drugs Sales Market Share by Country (2020-2025)

Table 36. Americas Neurodegenerative Drugs Revenue by Country (2020-2025) & (\$ millions)

Table 37. Americas Neurodegenerative Drugs Sales by Type (2020-2025) & (MT)

Table 38. Americas Neurodegenerative Drugs Sales by Application (2020-2025) & (MT)

Table 39. APAC Neurodegenerative Drugs Sales by Region (2020-2025) & (MT)

Table 40. APAC Neurodegenerative Drugs Sales Market Share by Region (2020-2025)

Table 41. APAC Neurodegenerative Drugs Revenue by Region (2020-2025) & (\$ millions)

Table 42. APAC Neurodegenerative Drugs Sales by Type (2020-2025) & (MT)

Table 43. APAC Neurodegenerative Drugs Sales by Application (2020-2025) & (MT)

Table 44. Europe Neurodegenerative Drugs Sales by Country (2020-2025) & (MT)

Table 45. Europe Neurodegenerative Drugs Revenue by Country (2020-2025) & (\$ millions)

Table 46. Europe Neurodegenerative Drugs Sales by Type (2020-2025) & (MT)

Table 47. Europe Neurodegenerative Drugs Sales by Application (2020-2025) & (MT)

Table 48. Middle East & Africa Neurodegenerative Drugs Sales by Country (2020-2025) & (MT)

Table 49. Middle East & Africa Neurodegenerative Drugs Revenue Market Share by Country (2020-2025)

Table 50. Middle East & Africa Neurodegenerative Drugs Sales by Type (2020-2025) & (MT)

Table 51. Middle East & Africa Neurodegenerative Drugs Sales by Application (2020-2025) & (MT)

Table 52. Key Market Drivers & Growth Opportunities of Neurodegenerative Drugs

Table 53. Key Market Challenges & Risks of Neurodegenerative Drugs

Table 54. Key Industry Trends of Neurodegenerative Drugs

Table 55. Neurodegenerative Drugs Raw Material

Table 56. Key Suppliers of Raw Materials

Table 57. Neurodegenerative Drugs Distributors List

Table 58. Neurodegenerative Drugs Customer List

Table 59. Global Neurodegenerative Drugs Sales Forecast by Region (2026-2031) & (MT)

Table 60. Global Neurodegenerative Drugs Revenue Forecast by Region (2026-2031) & (\$ millions)

Table 61. Americas Neurodegenerative Drugs Sales Forecast by Country (2026-2031) & (MT)

Table 62. Americas Neurodegenerative Drugs Annual Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 63. APAC Neurodegenerative Drugs Sales Forecast by Region (2026-2031) & (MT)

Table 64. APAC Neurodegenerative Drugs Annual Revenue Forecast by Region (2026-2031) & (\$ millions)

Table 65. Europe Neurodegenerative Drugs Sales Forecast by Country (2026-2031) & (MT)

Table 66. Europe Neurodegenerative Drugs Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 67. Middle East & Africa Neurodegenerative Drugs Sales Forecast by Country (2026-2031) & (MT)

Table 68. Middle East & Africa Neurodegenerative Drugs Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 69. Global Neurodegenerative Drugs Sales Forecast by Type (2026-2031) & (MT)

Table 70. Global Neurodegenerative Drugs Revenue Forecast by Type (2026-2031) & (\$ millions)

Table 71. Global Neurodegenerative Drugs Sales Forecast by Application (2026-2031) & (MT)

Table 72. Global Neurodegenerative Drugs Revenue Forecast by Application

(2026-2031) & (\$ millions)

Table 73. Novartis Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 74. Novartis Neurodegenerative Drugs Product Portfolios and Specifications

Table 75. Novartis Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 76. Novartis Main Business

Table 77. Novartis Latest Developments

Table 78. Pfizer Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 79. Pfizer Neurodegenerative Drugs Product Portfolios and Specifications

Table 80. Pfizer Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 81. Pfizer Main Business

Table 82. Pfizer Latest Developments

Table 83. Merck Serono Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 84. Merck Serono Neurodegenerative Drugs Product Portfolios and Specifications

Table 85. Merck Serono Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 86. Merck Serono Main Business

Table 87. Merck Serono Latest Developments

Table 88. Biogen Idec Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 89. Biogen Idec Neurodegenerative Drugs Product Portfolios and Specifications

Table 90. Biogen Idec Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 91. Biogen Idec Main Business

Table 92. Biogen Idec Latest Developments

Table 93. TEVA Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 94. TEVA Neurodegenerative Drugs Product Portfolios and Specifications

Table 95. TEVA Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 96. TEVA Main Business

Table 97. TEVA Latest Developments

Table 98. UCB Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 99. UCB Neurodegenerative Drugs Product Portfolios and Specifications

Table 100. UCB Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 101. UCB Main Business

Table 102. UCB Latest Developments

Table 103. Boehringer Ingelheim Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 104. Boehringer Ingelheim Neurodegenerative Drugs Product Portfolios and Specifications

Table 105. Boehringer Ingelheim Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 106. Boehringer Ingelheim Main Business

Table 107. Boehringer Ingelheim Latest Developments

Table 108. Sanofi Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 109. Sanofi Neurodegenerative Drugs Product Portfolios and Specifications

Table 110. Sanofi Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 111. Sanofi Main Business

Table 112. Sanofi Latest Developments

Table 113. GlaxoSmithKline Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 114. GlaxoSmithKline Neurodegenerative Drugs Product Portfolios and Specifications

Table 115. GlaxoSmithKline Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 116. GlaxoSmithKline Main Business

Table 117. GlaxoSmithKline Latest Developments

Table 118. Livzon Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 119. Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications

Table 120. Livzon Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 121. Livzon Pharmaceutical Main Business

Table 122. Livzon Pharmaceutical Latest Developments

Table 123. Haisco Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 124. Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications

Table 125. Haisco Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 126. Haisco Pharmaceutical Main Business

Table 127. Haisco Pharmaceutical Latest Developments

Table 128. Jingxin Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 129. Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications

Table 130. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 131. Jingxin Pharmaceutical Main Business

Table 132. Jingxin Pharmaceutical Latest Developments

Table 133. Dongcheng Biochemicals Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 134. Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolios and Specifications

Table 135. Dongcheng Biochemicals Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 136. Dongcheng Biochemicals Main Business

Table 137. Dongcheng Biochemicals Latest Developments

Table 138. Hisun Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 139. Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications

Table 140. Hisun Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 141. Hisun Pharmaceutical Main Business

Table 142. Hisun Pharmaceutical Latest Developments

Table 143. Luye Pharma Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 144. Luye Pharma Neurodegenerative Drugs Product Portfolios and Specifications

Table 145. Luye Pharma Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 146. Luye Pharma Main Business

Table 147. Luye Pharma Latest Developments

Table 148. Ark Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 149. Ark Pharmaceutical Neurodegenerative Drugs Product Portfolios and

Specifications

Table 150. Ark Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 151. Ark Pharmaceutical Main Business

Table 152. Ark Pharmaceutical Latest Developments

Table 153. Kanghong Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 154. Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications

Table 155. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 156. Kanghong Pharmaceutical Main Business

Table 157. Kanghong Pharmaceutical Latest Developments

Table 158. Huahai Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 159. Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications

Table 160. Huahai Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 161. Huahai Pharmaceutical Main Business

Table 162. Huahai Pharmaceutical Latest Developments

Table 163. BORA PHARMACEUTICALS Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 164. BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolios and Specifications

Table 165. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (MT), Revenue (\$ Million), Price (US\$/MT) and Gross Margin (2020-2025)

Table 166. BORA PHARMACEUTICALS Main Business

Table 167. BORA PHARMACEUTICALS Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Neurodegenerative Drugs
- Figure 2. Neurodegenerative Drugs Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Neurodegenerative Drugs Sales Growth Rate 2020-2031 (MT)
- Figure 7. Global Neurodegenerative Drugs Revenue Growth Rate 2020-2031 (\$ millions)
- Figure 8. Neurodegenerative Drugs Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)
- Figure 9. Neurodegenerative Drugs Sales Market Share by Country/Region (2024)
- Figure 10. Neurodegenerative Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
- Figure 11. Product Picture of NMDA
- Figure 12. Product Picture of SSRIs
- Figure 13. Product Picture of Dopamine Inhibitors
- Figure 14. Global Neurodegenerative Drugs Sales Market Share by Type in 2025
- Figure 15. Global Neurodegenerative Drugs Revenue Market Share by Type (2020-2025)
- Figure 16. Neurodegenerative Drugs Consumed in Parkinson's Disease
- Figure 17. Global Neurodegenerative Drugs Market: Parkinson's Disease (2020-2025) & (MT)
- Figure 18. Neurodegenerative Drugs Consumed in Huntington Disease
- Figure 19. Global Neurodegenerative Drugs Market: Huntington Disease (2020-2025) & (MT)
- Figure 20. Neurodegenerative Drugs Consumed in Amyotrophic Lateral Sclerosis
- Figure 21. Global Neurodegenerative Drugs Market: Amyotrophic Lateral Sclerosis (2020-2025) & (MT)
- Figure 22. Neurodegenerative Drugs Consumed in Alzheimer's Disease
- Figure 23. Global Neurodegenerative Drugs Market: Alzheimer's Disease (2020-2025) & (MT)
- Figure 24. Global Neurodegenerative Drugs Sale Market Share by Application (2024)
- Figure 25. Global Neurodegenerative Drugs Revenue Market Share by Application in 2025
- Figure 26. Neurodegenerative Drugs Sales by Company in 2025 (MT)

Figure 27. Global Neurodegenerative Drugs Sales Market Share by Company in 2025

Figure 28. Neurodegenerative Drugs Revenue by Company in 2025 (\$ millions)

Figure 29. Global Neurodegenerative Drugs Revenue Market Share by Company in 2025

Figure 30. Global Neurodegenerative Drugs Sales Market Share by Geographic Region (2020-2025)

Figure 31. Global Neurodegenerative Drugs Revenue Market Share by Geographic Region in 2025

Figure 32. Americas Neurodegenerative Drugs Sales 2020-2025 (MT)

Figure 33. Americas Neurodegenerative Drugs Revenue 2020-2025 (\$ millions)

Figure 34. APAC Neurodegenerative Drugs Sales 2020-2025 (MT)

Figure 35. APAC Neurodegenerative Drugs Revenue 2020-2025 (\$ millions)

Figure 36. Europe Neurodegenerative Drugs Sales 2020-2025 (MT)

Figure 37. Europe Neurodegenerative Drugs Revenue 2020-2025 (\$ millions)

Figure 38. Middle East & Africa Neurodegenerative Drugs Sales 2020-2025 (MT)

Figure 39. Middle East & Africa Neurodegenerative Drugs Revenue 2020-2025 (\$ millions)

Figure 40. Americas Neurodegenerative Drugs Sales Market Share by Country in 2025

Figure 41. Americas Neurodegenerative Drugs Revenue Market Share by Country (2020-2025)

Figure 42. Americas Neurodegenerative Drugs Sales Market Share by Type (2020-2025)

Figure 43. Americas Neurodegenerative Drugs Sales Market Share by Application (2020-2025)

Figure 44. United States Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 45. Canada Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 46. Mexico Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 47. Brazil Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 48. APAC Neurodegenerative Drugs Sales Market Share by Region in 2025

Figure 49. APAC Neurodegenerative Drugs Revenue Market Share by Region (2020-2025)

Figure 50. APAC Neurodegenerative Drugs Sales Market Share by Type (2020-2025)

Figure 51. APAC Neurodegenerative Drugs Sales Market Share by Application (2020-2025)

Figure 52. China Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 53. Japan Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 54. South Korea Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 55. Southeast Asia Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 56. India Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 57. Australia Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 58. China Taiwan Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 59. Europe Neurodegenerative Drugs Sales Market Share by Country in 2025

Figure 60. Europe Neurodegenerative Drugs Revenue Market Share by Country (2020-2025)

Figure 61. Europe Neurodegenerative Drugs Sales Market Share by Type (2020-2025)

Figure 62. Europe Neurodegenerative Drugs Sales Market Share by Application (2020-2025)

Figure 63. Germany Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 64. France Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 65. UK Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 66. Italy Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 67. Russia Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 68. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Country (2020-2025)

Figure 69. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Type (2020-2025)

Figure 70. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Application (2020-2025)

Figure 71. Egypt Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 72. South Africa Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 73. Israel Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 74. Turkey Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 75. GCC Countries Neurodegenerative Drugs Revenue Growth 2020-2025 (\$ millions)

Figure 76. Manufacturing Cost Structure Analysis of Neurodegenerative Drugs in 2025

Figure 77. Manufacturing Process Analysis of Neurodegenerative Drugs

Figure 78. Industry Chain Structure of Neurodegenerative Drugs

Figure 79. Channels of Distribution

Figure 80. Global Neurodegenerative Drugs Sales Market Forecast by Region (2026-2031)

Figure 81. Global Neurodegenerative Drugs Revenue Market Share Forecast by Region (2026-2031)

Figure 82. Global Neurodegenerative Drugs Sales Market Share Forecast by Type

(2026-2031)

Figure 83. Global Neurodegenerative Drugs Revenue Market Share Forecast by Type
(2026-2031)

Figure 84. Global Neurodegenerative Drugs Sales Market Share Forecast by
Application (2026-2031)

Figure 85. Global Neurodegenerative Drugs Revenue Market Share Forecast by
Application (2026-2031)

I would like to order

Product name: Global Neurodegenerative Drugs Market Growth 2025-2031

Product link: <https://marketpublishers.com/r/G9ED8B4E7A9DEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9ED8B4E7A9DEN.html>